Sponsors (21)
The bill improves safety and informed use for people with food allergies and gluten-related disorders through clearer drug labeling, likely reducing some healthcare costs, while imposing compliance and relabeling costs on manufacturers (especially smaller firms) and creating transitional uncertainty for health systems.
People with food allergies or gluten-related disorders will be able to identify when a medicine contains or is derived from major food allergens and which gluten-containing grain (wheat, barley, rye, hybrids) is present, reducing the risk of accidental exposures and severe allergic reactions.
Clearer allergen/grain labeling on medicines may reduce emergency visits, hospitalizations, and other healthcare utilization from accidental exposures, lowering medical costs for affected patients and public programs.
Smaller drug makers, compounders, and specialty manufacturers may face new testing, verification, and relabeling compliance burdens that increase administrative costs and could reduce product availability.
Drug manufacturers will incur costs to change labeling that could be passed on to consumers through higher drug prices.
If regulatory implementation guidance is delayed or inconsistent during the transition, pharmacies, hospitals, and health systems may face uncertainty about which products comply, complicating procurement and patient care.
Based on analysis of 2 sections of legislative text.
Requires labels on human-intended drugs to disclose and identify any major food allergen or gluten-containing grain ingredient and, if applicable, specify the gluten grain type.
Requires human-intended drug labels to disclose when a product contains (or is derived from) a major food allergen or a gluten-containing grain and to identify each such ingredient and, if applicable, the specific type of gluten-containing grain. The labeling requirement becomes effective on the earlier of a date set by the HHS Secretary or two years after the law is enacted.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug intended for human use to identify each ingredient in such drug that is, or is derived directly or indirectly from, a major food allergen or a gluten-containing grain, and for other purposes.
Introduced June 6, 2025 by Kelly Morrison · Last progress June 6, 2025